Abstract: Invasive meningococcal disease occurs worldwide causing an estimated 50,000-135,000 deaths each year in addition to signifi cant sequelae. In developed countries the disease is usually sporadic but outbreaks and epidemics, usually due to serogroups B and C, have occurred. In the US, an increasing number of cases are due to serogroup Y. In developing nations, epidemics due to serogroups A and more recently W-135, are common. The tetravalent meningococcal conjugate vaccine to serogroups A, C, Y, and W-135 (MCV4) has been demonstrated to be highly immunogenic and promote immune memory. This article will describe the rationale for the vaccine and its potential role to signifi cantly decrease mortality and morbidity of meningococcal disease in those areas and populations at greatest risk from these serogroups.
accounted for 28% and 27% during that year (CDC 2007) . In New Zealand, an epidemic of predominantly serogroup B meningococcal disease has recorded disease rates as high as approximately 500 per 100,000 in Pacifi c children less then 1 year of age compared with less then 50 per 100,000 children of European descent (O'Hallahan et al 2004) .
Invasive meningococcal disease usually occurs in persons who are seronegative and subsequently acquire N. meningitidis from crowding such as among military recruits and freshmen college students living in residence halls (Bruce et al 2001) . The nasopharyngeal carriage rate of N. meningitidis has been shown to increase rapidly for fi rst year university students living in residence halls (Neal et al 2000) . Exposure to tobacco smoke and alcohol-related behaviors are other potential risk factors for meningococcal disease in this population (Harrison et al 1999) .
Once N. meningitidis attaches to the nasopharyngeal mucosal cells, replicates, and establishes a carrier state, multiple factors determine the occurrence of IMD including the virulence of the organism and factors affecting host susceptibility (Granoff 2004 ). The spleen is responsible for clearing meningococci from the blood and anatomic splenectomy has resulted in overwhelming meningococcal sepsis (Condon et al 1994) . Patients with functional hypoor asplenia are also at increased risk for disease (Granoff 2004) . Defi ciencies of terminal complement component, properdin, factor D, and mannan-binding lectin (MBL) have been associated with increased susceptibility to meningococcal infection (Pollard and Frasch 2001) . The absence of serum bactericidal antibodies (SBAs) to human complement (hSBAs) to serogroup C meningococci, as demonstrated by a titer of less then 1:4, was associated with an increased risk of meningococcal disease in military recruits (Goldschneider et al 1969a) . It was later demonstrated that SBAs to rabbit complement (rSBAs) with a titer of less then 1:8 also predict susceptibility to meningococcal disease (Borrow et al 2001) . Conversely, a hSBA titer to serogroup C of Ն4 is considered protective while a rSBA titer of Ն8 is correlated with at least short-term protection (Borrow et al 2005) .
Burden of illness
Vieusseux in Switzerland fi rst described epidemic meningococcal disease in 1805, but Weichselbaum fi rst identifi ed the bacterium in 1887 (Barquet et al 1999; Rosenstein et al 2001) . Meningitis occurs in about 50% of patients, and in older children and adults is accompanied by sudden headache, fever, stiff neck, and sometimes nausea, vomiting, and photophobia . In infants and very young children, fever, poor feeding, and lethargy may be seen initially while nuchal rigidity presents later in the course of the illness (Granoff 2004) . A rash is often present but may vary from maculopapular to the classic petechial or purpuric rash. Meningococcal sepsis or meningococcemia occurs in 5%-20% of IMD . It is characterized by sudden fever, petechial or purpuric rash, hypotension progressing to shock, acute adrenal hemorrhage (Waterhouse-Friederichsen syndrome), and multiorgan failure (Rosenstein, Perkins et al 2001) . Other forms of IMD include pneumonia, arthritis, pericarditis, and cellulitis (van Deuren et al 2000) .
The overall case-fatality rate for IMD in the US is approximately 9%-12%, even with appropriate antibiotic treatment, and that for meningococcemia is as high as 40% . However, the fatality rate can vary according to the affected population and the meningococcal serogroup. In New Zealand, the average case-fatality rate for serogroup B IMD is 4.3% (O'Hallahan et al 2004) . In a study of 295 cases of IMD in Maryland, USA from 1992 to 1999, persons ages 15-24 years old accounted for 24% of IMD cases and had a fatality rate of 23% compared with 4.6% of those younger than 15 years and 17% of those older than 24 years (Harrison et al 2001) . Of the 14 fatalities for which serogroup was known, serogroups C and Y accounted for 57% and 29%, respectively, of fatalities in this age group (Harrison et al 2001) . Consequently, more then 85% of these deaths were potentially preventable by the tetravalent (Groups A, C, Y, and W-135) meningococcal vaccines.
Invasive meningococcal disease may also cause sequelae such as hearing loss, neurologic defi cits, or limb loss in up to 11%-19% of cases . A review of IMD in Barcelona from 1987 to 1992 found a sequelae rate of 8.2% for meningitis, 3.5% for meningococcemia with meningitis, and 1.5% for meningococcemia with an overall rate of 4% (Barquet et al 1999) . All patients who had neurologic sequelae had meningitis while meningococcemia was associated with sequelae such as limb amputation (Barquet et al 1999) .
Outbreaks of meningococcal disease
Household contacts of patients with IMD have a 500-800 times greater risk of meningococcal disease than the general rate and should be given chemoprophylaxis (Bilukha and Rosenstein 2005) . They are candidates for immunization with meningococcal vaccine, but this does not substitute for chemoprophylaxis because of the time delay in developing immunity. Chemoprophylaxis should also be given to close contacts including child-care center contacts, anyone directly exposed to the patient's oral or respiratory secretions, and passengers who sat on either side of the index-patient on a fl ight lasting Ͼ/= 8 hours (MMWR 2001a; Bilukha and Rosenstein 2005) . Because systemic therapy other than ceftriaxone or other third-generation cephalosporin might not eradicate N. meningitidis from the nasopharynx, patients treated for IMD with other agents such as penicillin should also receive chemoprophylaxis (Abramson and Spika 1985; Bilukha and Rosenstein 2005) . Chemoprophylaxis is ideally given within 24 hours of identifi cation in the index patient and is of little value Ͼ14 days after disease onset (Bilukha and Rosenstein 2005) . Table 1 lists currently recommended antibiotic prophylaxis for meningococcal disease. Fluoroquinolone-resistant N. meningitidis has been reported in Argentina, Australia, China, France, India, Spain, and most recently in the northern US (MMWR 2008) . One study found azithromycin comparable in effi cacy to rifampin in eradicating nasopharyngeal coverage of N. meningitis (Girgis 1998) . When fl uoroquinolone-resistant meningococcal disease is identifi ed, interim CDC recommendations are to give a single dose of 500 mg azithromycin for exposed persons Ն15 years old or 10 mg/kg body weight for those under 15 years old (MMWR 2008) .
The United States Centers for Disease Control and Prevention (CDC) defi ne outbreaks as three or more confi rmed or probable cases of meningococcal disease in Յ3 months among persons residing in the same area who are not close contacts of each other with a primary disease attack rate of Ն10 cases/100,000 persons (Bilukha and Rosenstein 2005) . In the circumstance of a confi rmed outbreak, public health personnel should consider vaccinating the population at risk. Mass chemoprophylaxis is not recommended except for outbreaks involving populations in a limited setting such as school or for a serogroup B outbreak in those countries where a vaccine is not available (Bilukha and Rosenstein 2005) .
Meningococcal polysaccharide vaccines
Goldschneider and colleagues demonstrated that transplacental passage of antibodies to meningococci occurred resulting in passively acquired immunity to infection (Goldschneider et al 1969b) . In addition they found that military recruits developed bactericidal antibodies to their own meningococcal isolates as a response to their carrier state (Goldschneider et al 1969b) . Animal and human testing subsequently demonstrated that serogroups A and C polysaccharides stimulated immunogenicity (Gotschlich et al 1969) . This led to the development of polysaccharide vaccines that were effective in preventing group C disease in US military recruits and controlling group A epidemics in Africa (Jodar et al 2002) . The tetravalent polysaccharide vaccine to serogroups A, C, Y, and W-135 (MPSV4, Menomune ® -A,C,Y,W-135, Sanofi Pasteur, Inc., Swiftwater, Pennsylvania, US) was 85% effi cacious in preventing group C meningococcal disease during an outbreak in Texas, USA (Rosenstein et al 1998) .
The MPSV4 vaccine is T cell-independent and the serogroup C component is poorly immunogenic in children less then 18-24 months old while the serogroup A polysaccharide does not induce an immune response comparable to adults until ages 4-5 years (MMWR 2000) . In children less then 5 years, antibody levels to group A and C polysaccharides decrease signifi cantly within 3 years after a single vaccine dose (MMWR 2000) . The vaccine also does not stimulate immune memory, and revaccination with serogroup C capsular polysaccharide vaccines often results in a hypo-responsive antibody response to group C polysaccharide in children and adults (Granoff et al 1998; MacDonald et al 1998; Danzig 2004) . It has been posited that repeated stimulation of B cells with the T-cell independent plain polysaccharide vaccine results in terminal differentiation of B cells to produce plasma cells and depletes the pool of specifi c B cells (Granoff and Pollard 2007) . The serogroup B meningococcal polysaccharide is poorly immunogenic and the resulting IgG antibodies have poor complement bactericidal activity. In addition, the serogroup B capsular polysaccharide is structurally similar to a nerve cell molecule present in developing neural tissue and small amounts of adult tissue (Danzig 2004) . Vaccines for serogroup B that utilize the outer membrane vesicle (OMV) of N. meningitidis are under trial in a number of countries (Borrow et al 2005) . Their use is beyond the scope of this article.
The United Kingdom (UK) experience with conjugate meningococcal C vaccine
Polysaccharides conjugated to carrier proteins induce T-cell dependent immunity (Granoff 2004) . In November, 1999, the UK initiated a program to vaccinate all children with conjugate meningococcal C vaccine. Two vaccine brands used CRM197 as the carrier protein (Wyeth and Novartis, Canada, QC) and one used tetanus toxoid (Baxter Bioscience, IL, USA) (Borrow and Miller 2006) . The vaccine was given to infants at 2, 3, and 4 months of age, with a single dose catch-up to all children ages 1-18 years old and two doses for infants 5-11 months old (Borrow and Miller 2006) . These vaccines were demonstrated to be immunogenic and effi cacious in infants, children, and adolescents. The number of cases of serogroup C IMD in adolescents 15-17 years old decreased by 76% from Jan 1 to Sept 30, 2000 compared with the corresponding period in 1999 and vaccine effi cacy was estimated at 97% in teenagers (Ramsay et al 2001) . Cases of serogroup C IMD in toddlers decreased by 34% during this period, but vaccine effi cacy was estimated at 92% (Ramsay et al 2001) . More than 1 year later, vaccine effectiveness decreased signifi cantly in infants 2-4 months at initial immunization while effectiveness in older children and especially adolescents persisted (Trotter et al 2004) .
The nasopharyngeal carriage of meningococcal serogroup C bacteria in students aged 15-17 years was found to decrease by 66% 1 year later (Maiden and Stuart 2002) . The attack rate of serogroup C IMD subsequently decreased by 67% overall in un-immunized children and adolescents from July 2001 to June 2002 compared with July 1998 to June 1999 (Ramsay et al 2003) . Consequently, there is evidence of herd immunity in unvaccinated members of the population or those in whom antibody levels have waned if a high enough proportion of the population is vaccinated.
Safety and effi cacy of the tetravalent meningococcal conjugate vaccine
Three separate groups of 30 healthy US adults ages 18-55 years were given a single dose of tetravalent meningococcal conjugate vaccine containing either 1, 4, or 10 μg of each capsular polysaccharide conjugated to diphtheria toxoid. Twenty-eight days after immunization, the percentage of recipients with SBA titers of Ն8 was 100%, 89%-100%, 88%, and 91% for serogroups A, C, Y, and W-135, respectively (Campbell et al 2002) . Mild to moderate local reactions such as injection site erythema and swelling occurred in over 50%-90% of subjects and in each dose group, 41%-50% reported at least one systemic reaction such as headache and malaise. One subject experienced severe pain, chills, and malaise with local tenderness and vomiting that resolved within 2 days (Campbell et al 2002) . Another study randomized over 800 adolescents (ages 11-18 years) to MPSV4 or the meningococcal conjugate vaccine containing 4 μg of capsular polysaccharide each from serogroups A, C, Y, W-135 (MCV4). Both vaccines were highly immunogenic to all four serogroups, although the MCV4 recipients reported more local reactions than the MPSV4 group (69% vs 30%) (Keyserling et al 2005) . Follow-up at 3 years demonstrated persistence of SBA and booster responses to MCV4 consistent with immune memory that was not present in the MPSV4 group (Keyserling et al 2005) . In January 2005, the US Food and Drug Administration (FDA) licensed Meningococcal Polysaccharide (serogroups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (MCV4, Menactra ® , Sanofi Pasteur, Inc., Swiftwater, PA, US) for the immunization of adolescents and adults aged 11-55 years age (Bilukha and Rosenstein 2005) .
A US study compared safety and immunogenicity of MCV4 with MPSV4 in 2-to 10-year-old children. The percentage of children with SBA titers Ն1/128 ranged from 81%-97% across the 4 serogroups in the MCV4 group versus 73%-93% for the MPSV4 group (Pichichero et al 2005) . Mild to moderate local and systemic reactions of short duration were common and comparable in both groups (Pichichero et al 2005) . A subgroup of children vaccinated with MCV4 were given a challenge dose of MPSV4 23-36 months later. They demonstrated an increase in IgG antibody and antibody avidity consistent with the induction of immune memory (Pichichero et al 2006) . A UK study gave MCV4 to children 2 to Ͻ5 years old who had previously received the monovalent meningococcal C conjugate vaccine. All 44 children developed SBA titers Ն8 to all four serogroups with a booster response observed to serogroup C (El Bashir et al 2006) . In October, 2007 the FDA subsequently licensed MCV4 for use in children aged 2-10 years (MMWR 2007) .
Another study compared vaccine doses of 1, 4, and 10 μg for each of the four polysaccharide serogroups conjugated to diphtheria toxoid that were given to infants at 2, 4, and 6 months of age. Presumed protective SBA levels Ͼ/= 1:8 varied from 54% to 92% 1 month after the primary series depending upon vaccine serogroup and polysaccharide dose. A polysaccharide content of 10 μg was associated with more frequent local reactions but not with a corresponding increase in immunogenicity than lower doses of each serogroup (Rennels et al 2004) . Consequently, there is no advantage to having a higher dose of the polysaccharide serogroups in the diphtheria toxoid conjugate vaccine.
Guillain-Barré Syndrome (GBS) among MCV4 recipients
In October 2005, reports suggested a possible association of GBS with MCV4, and the ACIP recommended that persons with a past history of GBS not be vaccinated with MCV4 unless they are at high risk for meningococcal disease (MMWR 2006) . As of October 2007, there were 24 confi rmed reports of GBS after administration of MCV4 to the US Vaccine Adverse Event Reporting System (Clark 2007) . However, no cases of GBS were reported among 11-to 19-year-olds within 6 weeks after more then 200,000 doses of MCV4 from the Vaccine Safety Datalink project (Clark 2007) . The excess risk of GBS is currently estimated to be from 0.4 to 1.3 per million doses (Clark 2007) . The benefi ts of MCV4 are currently considered to signifi cantly outweigh the potential risks, except in patients with a prior history of GBS (see contraindications and precautions). Table 2 lists the recommendations for the use of MCV4 made by the CDC Advisory Committee on Immunization Practices. It is routinely recommended for all US children aged 11-18 years, including those at additional risk. The vaccine is now recommended for use in at-risk children ages 2-10 years (MMWR 2007) and at-risk adults aged 19-55 years. Persons aged 2-55 years who continue to be at risk for meningococcal infection, despite having been vaccinated with MPSV4 3 or more years earlier, are also candidates for revaccination with MCV4 (Bilukha and Rosenstein 2005) . The FDA has not approved the vaccine for use in children younger then 2 years or adults older then 55 years. Consequently MPSV4 could be substituted for adults older than 55 years.
Indications for use of MCV4

Contraindications and precautions to use of MCV4
Administration of MCV4 is contraindicated among persons known to have a severe allergic reaction to any component of the vaccine, including diphtheria toxoid or to natural latex rubber. MCV4 is an inactivated vaccine and may be given to immunosuppressed persons, but this may result in suboptimal immune response. No data are available about its safety during pregnancy (Bilukha and Rosenstein 2005) . A history of GBS is considered a precaution to administering MCV4, and MPSV4 is an acceptable short-term alternative providing protection for approximately 3-5 years (MMWR 2007) .
Cost effectiveness of MCV4
Cost effectiveness of meningococcal vaccination has been somewhat controversial, especially with the polysaccharide MPSV4 vaccine in developed countries where the vast majority of meningococcal cases are sporadic. One analysis estimated that vaccinating all US college freshmen living in dormitories with MPSV4 would cost US$0.6-$1.9 million per case averted and US$7-20 million per death averted (Scott 2002) . This analysis did not consider the cost of chemoprophylaxis or vaccination in the event of an outbreak, the cost of rehabilitating IMD survivors with sequelae, and the anxiety and stress due to an outbreak in the university community (Scott 2002) . It has been estimated that routine vaccination of US adolescents 11 years old with MCV4 would prevent 270 cases of meningococcal disease and 36 deaths over 22 years at a cost of US$633,000 per case and US$121,000 per life-year saved (Shepard et al 2005) . Although fi nancial costs of prevention are high, the mortality and morbidity of IMD warrant the routine use of MCV4 in adolescents.
Conclusion and future issues
In addition to the devastation of the disease, considerable anxiety often accompanies an outbreak of IMD in the community or affected regions. The MCV4 has demonstrated immunogenicity to serogroups A, C, Y, and W-135 with an acceptable degree of reactogenicity. Based on the experience with conjugated meningococcal C vaccine in the UK, it is believed that MCV4 will have a similar impact on IMD caused by those serogroups. Because it is a conjugate vaccine, it is believed that the immunity provided by this vaccine will last longer then that provided by MPSV4. However, data suggest that serologic correlates of immunity to serogroup C may wane rapidly after 1 year in young children (Snape et al 2005; Borrow and Miller 2006) . The conjugate vaccines prime for immune memory but it is not clear that this occurs quickly or suffi ciently enough to provide protection from disease (Borrow and Miller 2006) . Protection from disease may therefore depend on persistence of protective antibody levels and herd immunity. Thus far, antibody persistence in older children and adolescents appears good but it remains to be seen whether a booster dose of vaccine will be required at some future date.
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